Details of the Drug Combinations

General Information of This Drug (ID: DMD7L94)

• Drug Name: Palbociclib (DMD7L94)
• Synonyms: 571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Approved [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 2 [2]; Schizophrenia; ICD 11: 6A20; Status: Terminated [3]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

17 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dorsomorphin + Palbociclib	DCYBB18	Dorsomorphin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Dorsomorphin + Palbociclib	DCW91GI	Dorsomorphin	Primitive neuroectodermal tumor (Cell Line: TC-32)	[4]
MK-2206 + Palbociclib	DC16NQC	MK-2206	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Palbociclib + Trametinib	DCLWZOC	Trametinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Palbociclib + JQ1	DCI500M	JQ1	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Palbociclib + THAPSIGARGIN	DC7PZ53	THAPSIGARGIN	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Palbociclib + THAPSIGARGIN	DCONAT1	THAPSIGARGIN	Primitive neuroectodermal tumor (Cell Line: TC-32)	[4]
Palbociclib + Ciclopirox	DC72GQL	Ciclopirox	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Palbociclib + IMD-0354	DCA8BD3	IMD-0354	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Palbociclib + BMS-754807	DC29FGP	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Palbociclib + PHA848125	DCIFUAV	PHA848125	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Palbociclib + PF-562271	DCQCGGA	PF-562271	Primitive neuroectodermal tumor (Cell Line: TC-32)	[4]
Palbociclib + Afatinib	DCAUDSY	Afatinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Palbociclib + Auranofin	DC2KFVR	Auranofin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Palbociclib + Auranofin	DCKAKVD	Auranofin	Primitive neuroectodermal tumor (Cell Line: TC-32)	[4]
Raloxifene + Palbociclib	DCJSXE4	Raloxifene	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Raloxifene + Palbociclib	DC602ZD	Raloxifene	Primitive neuroectodermal tumor (Cell Line: TC-32)	[4]

13 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dexamethasone + Palbociclib	DC19WBF	Dexamethasone	Recurrent B Acute Lymphoblastic Leukemia	[5]
HKI-272 + Palbociclib	DCHG5OU	HKI-272	Advanced Malignant Solid Neoplasm	[6]
Palbociclib + Letrozole	DCKLEF1	Letrozole	Neoplasms	[7]
Palbociclib + Letrozole	DCKM9VL	Letrozole	Breast Neoplasms	[8]
Palbociclib + Letrozole	DCMXE98	Letrozole	Anatomic Stage I Breast Cancer AJCC v8	[9]
Palbociclib + Carboplatin	DCBDHE4	Carboplatin	Solid Neoplasm	[10]
PF-05212384 + Palbociclib	DCPDJND	PF-05212384	Lung Cancer Squamous Cell	[11]
Arry-162 + Palbociclib	DC792WE	Arry-162	Metastatic Colorectal Carcinoma	[12]
Arry-162 + Palbociclib	DC9QCOH	Arry-162	Malignant Solid Neoplasm	[13]
Fulvestrant + Palbociclib	DCDAWVA	Fulvestrant	Metastatic Breast Carcinoma	[14]
Fulvestrant + Palbociclib	DC6LL1C	Fulvestrant	Metastatic Breast Cancer	[15]
Fulvestrant + Palbociclib	DCIR35B	Fulvestrant	Estrogen Receptor Positive	[16]
Goserelin + Palbociclib	DCHIMNL	Goserelin	Breast Neoplasms	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [2] ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health.
• [3] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] ClinicalTrials.gov (NCT03472573) Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
• [6] ClinicalTrials.gov (NCT03065387) Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
• [7] ClinicalTrials.gov (NCT01684215) A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
• [8] ClinicalTrials.gov (NCT01740427) A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
• [9] ClinicalTrials.gov (NCT03774472) Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
• [10] ClinicalTrials.gov (NCT02897375) Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
• [11] ClinicalTrials.gov (NCT03065062) Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
• [12] ClinicalTrials.gov (NCT03981614) Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
• [13] ClinicalTrials.gov (NCT05554367) Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
• [14] ClinicalTrials.gov (NCT02778685) Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
• [15] ClinicalTrials.gov (NCT02491983) Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
• [16] ClinicalTrials.gov (NCT03377101) Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer